A Concern that Drug Companies cannot Ignore

House of Commons Health Committee (April 2005). The Influence of the Pharmaceutical Industry [www.parliament.uk/parliamentary_committees/health_committee]

Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ 2004; 328: 1217

Dyer O. GlaxoSmithKline to set up comprehensive online clinical trials register. BMJ 2004; 329: 590

Drug company to make its trial results public. BMJ 2004; 329: 366

Pharmaceutical Research Manufacturers of America [Clinical Study Results website: www.clinicalstudyresults.org/]

De Angelis C. , Drazen J.M. , Frizelle F.A. . Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 2004; 364: 911–12

Couser W. , Drueke T. , Halloran P. . A uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation. Transplantation 2005; 79: 751

Abbasi K. , Godlee F. New steps in trial registration. BMJ 2005; 330: 1222–3

World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 [www.wma.net/e/policy/b3.htm]

Barnett A. Revealed: how drug firms ‘hoodwink’ medical journals. The Observer, 7 December 2003 [observer.guardian.co.uk/uk_news?story/o,6903,1101680,11.html]

Sharp D. A ghostly crew. Lancet 1998; 351: 1076

Jacobs A. , Wager E. European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 2005; 21: 317–21

Eaton L. Medical editors issue guidance on ghost writing. BMJ 2005; 330: 988

World Association of Medical Editors. Policy Statement: Ghost Writing Initiated by Commercial Companies [www.wame.org/wamestmt.htm#ghost]

Wager E. , Field E.A. , Grossman L. Good Publication Practice for pharmaceutical companies: why we need another set of guidelines. Curr Med Res Opin 2003; 19: 149–54

Pearn J. Publication: an ethical imperative. BMJ 1995; 310: 1313–15

Chalmers I. Lessons for research ethics committees. Lancet 2002; 359: 174

Melzer D. New drug treatment for Alzheimer's disease: lessons for healthcare policy. BMJ 1998; 316: 762–4